(Q50082366)

24 February 2018

title

Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. (English)

1 reference

24 February 2018

1 reference

9

Gordon Dougan

1 reference

24 February 2018

author name string

Christine Hale

1

1 reference

24 February 2018

Frances Bowe

2

1 reference

24 February 2018

Derek Pickard

3

1 reference

24 February 2018

Simon Clare

4

1 reference

24 February 2018

Jean-Francois Haeuw

5

1 reference

24 February 2018

Ultan Powers

6

1 reference

24 February 2018

Nathalie Menager

7

1 reference

24 February 2018

Pietro Mastroeni

8

1 reference

24 February 2018

language of work or name

English

0 references

publication date

20 March 2006

1 reference

24 February 2018

published in

Vaccine

1 reference

24 February 2018

volume

24

1 reference

24 February 2018

issue

20

1 reference

24 February 2018

page(s)

4312-4320

1 reference

24 February 2018

Physical, Chemical, Antigenic, and Immunologic Characterization of Polygalacturonan, Its Derivatives, and Vi Antigen from Salmonella typhi

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Vi-deficient and nonfimbriated mutants of Salmonella typhi agglutinate human blood type antigens and are hyperinvasive.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Vi-Suppressed wild strain Salmonella typhi cultured in high osmolarity is hyperinvasive toward epithelial cells and destructive of Peyer's patches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

The Vi capsular antigen of Salmonella enterica serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Precise excision of the large pathogenicity island, SPI7, in Salmonella enterica serovar Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Composition, acquisition, and distribution of the Vi exopolysaccharide-encoding Salmonella enterica pathogenicity island SPI-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Salmonella enterica serovar Dublin strains which are Vi antigen-positive use type IVB pili for bacterial self-association and human intestinal cell entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

The Vi antigen of Salmonella typhi: molecular analysis of the viaB locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Identification of six open reading frames in the Salmonella enterica subsp. enterica ser. Typhi viaB locus involved in Vi antigen production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Complete nucleotide sequence and molecular characterization of ViaB region encoding Vi antigen in Salmonella typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

A new typhoid vaccine composed of the Vi capsular polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Vaccination in the neonatal period and early infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Neonatal and early life vaccinology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Characterization and development of T-Cell immune responses in B-cell-deficient (Igh-6(-/-)) mice with Salmonella enterica serovar Typhimurium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Immunity induced by live attenuated Salmonella vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Correlates of protection induced by live Aro- Salmonella typhimurium vaccines in the murine typhoid model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Immunomodulation using bacterial enterotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Immunity to systemic Salmonella infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

7 January 2021

Evolutionary genetic relationships of clones of Salmonella serovars that cause human typhoid and other enteric fevers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

7 January 2021

Differential early interactions between Salmonella enterica serovar Typhi and two other pathogenic Salmonella serovars with intestinal epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

7 January 2021

Host restriction phenotypes of Salmonella typhi and Salmonella gallinarum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.002

7 January 2021

Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever

1 reference

12 December 2020

Comparison of ViaB regions of Vi-positive organisms

1 reference

12 December 2020

Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi

1 reference

12 December 2020

Genetic regulation of variable Vi antigen expression in a strain of Citrobacter freundii

1 reference

12 December 2020

Conjugate vaccines against bacterial infections: typhoid fever

1 reference

12 December 2020

Mechanism of the protective action of anti-Salmonella IgM in experimental mouse salmonellosis.

1 reference

12 December 2020

Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine

1 reference

12 December 2020

Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China

1 reference

12 December 2020

Characterization of the Salmonella paratyphi C Vi polysaccharide

1 reference

12 December 2020

The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application

1 reference

12 December 2020

Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

1 reference

12 December 2020

The global burden of typhoid fever

1 reference

12 December 2020

The immunological responses observed in field studies in Africa with group A meningococcal vaccines

1 reference

12 December 2020

Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

1 reference

12 December 2020

Physico-chemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA

1 reference

12 December 2020

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker

1 reference

12 December 2020

Role of the Vi antigen of Salmonella typhi in resistance to host defense in vitro.

1 reference

12 December 2020

10.1016/J.VACCINE.2006.03.002

Identifiers

DOI

1 reference

24 February 2018

1 reference

24 February 2018